1. Rosenblum D, Joshi N, Tao W, et al (2018) Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 9:1410
2. Golombek SK, May J-N, Theek B, et al (2018) Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev
3. Mitchell MJ, Jain RK, Langer R (2017) Engineering and physical sciences in oncology: challenges and opportunities. Nat Rev Cancer 17:659
4. Zhao W, Zhuang S, Qi X-R (2011) Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine 6:3087
5. Deshpande PP, Biswas S, Torchilin VP (2013) Current trends in the use of liposomes for tumor targeting. Nanomedicine 8:1509–1528
6. Muhamad N, Plengsuriyakarn T, Na-Bangchang K (2018) Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine 13:3921
7. Yoo J, Park C, Yi G, et al (2019) Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers (Basel) 11:640
8. Mashreghi M, Azarpara H, Bazaz MR, et al (2018) Angiogenesis biomarkers and their targeting ligands as potential targets for tumor angiogenesis. J Cell Physiol 233:2949–2965
9. Mura S, Nicolas J, Couvreur P (2013) Stimuli-responsive nanocarriers for drug delivery. Nat Mater 12:991–1003
10. Ganta S, Devalapally H, Shahiwala A, Amiji M (2008) A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control release 126:187–204
11. Liu M, Du H, Zhang W, Zhai G (2017) Internal stimuli-responsive nanocarriers for drug delivery: Design strategies and applications. Mater Sci Eng C 71:1267–1280
12. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674
13. Rajabi M, Mousa SA (2017) The role of angiogenesis in cancer treatment. Biomedicines 5:34
14. Chen L, Endler A, Shibasaki F (2009) Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Exp Mol Med 41:849–857
15. Zhou Y, Maiti M, Sharma A, et al (2018) Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy. J Control Release 288:14–22
16. Maleki MF, Jafari A, Mirhadi E, et al (2019) Endogenous Stimuli-Responsive Linkers in Nanoliposomal Systems for Cancer Drug Targeting. Int J Pharm 118716
17. Kiyose K, Hanaoka K, Oushiki D, et al (2010) Hypoxia-sensitive fluorescent probes for in vivo real-time fluorescence imaging of acute ischemia. J Am Chem Soc 132:15846–15848
18. Kulkarni P, Haldar MK, Katti P, et al (2016) Hypoxia responsive, tumor penetrating lipid nanoparticles for delivery of chemotherapeutics to pancreatic cancer cell spheroids. Bioconjug Chem 27:1830–1838
19. Kamath SA, Kummerow FA, Narayan KA (1971) A simple procedure for the isolation of rat liver microsomes. Febs Lett 17:90–92
20. Wang Y, Shang W, Niu M, et al (2019) Hypoxia-active nanoparticles used in tumor theranostic. Int J Nanomedicine 14:3705
21. Zbaida S, Levine WG (1991) A novel application of cyclic voltammetry for direct investigation of metabolic intermediates in microsomal azo reduction. Chem Res Toxicol 4:82–88
22. Willstätter R, Benz M (1906) Zur kenntniss der Azophenole. Berichte der Dtsch Chem Gesellschaft 39:3492–3503
23. Mashreghi M, Zamani P, Moosavian SA, Jaafari MR (2020) Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma. Nanoscale Res Lett 15:101. https://doi.org/10.1186/s11671-020-03334-9
24. Karimi M, Gheybi F, Zamani P, et al (2020) Preparation and characterization of stable nanoliposomal formulations of Curcumin with high loading efficacy: In vitro and in vivo anti-tumor study. Int J Pharm 119211
25. Brownlee WJ, Seib FP (2018) Impact of the hypoxic phenotype on the uptake and efflux of nanoparticles by human breast cancer cells. Sci Rep 8:1–11
26. Joshi U, Filipczak N, Khan MM, et al (2020) Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells. Int J Pharm 590:119915
27. Hamedinasab H, Rezayan AH, Mellat M, et al (2020) Development of chitosan-coated liposome for pulmonary delivery of N-acetylcysteine. Int J Biol Macromol 156:1455–1463
28. Suk JS, Xu Q, Kim N, et al (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–51
29. Bai S, Gupta V, Ahsan F (2009) Cationic liposomes as carriers for aerosolized formulations of an anionic drug: safety and efficacy study. Eur J Pharm Sci 38:165–171
30. Kiraga Ł, Cheda Ł, Taciak B, et al (2018) Changes in hypoxia level of CT26 tumors during various stages of development and comparing different methods of hypoxia determination. PLoS One 13:e0206706
31. Tacar O, Sriamornsak P, Dass CR (2013) Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 65:157–170
32. Wang L, Chen Q, Qi H, et al (2016) Doxorubicin-induced systemic inflammation is driven by upregulation of toll-like receptor TLR4 and endotoxin leakage. Cancer Res 76:6631–6642
33. Filion MC, Phillips NC (1997) Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta (BBA)-Biomembranes 1329:345–356
34. Betker JL, Anchordoquy TJ (2015) Relating toxicity to transfection: using sphingosine to maintain prolonged expression in vitro. Mol Pharm 12:264–273